Humulin S (Soluble)

Humulin S (Soluble) is a recombinant human insulin product marketed in the European Union. Its active ingredient is insulin human produced by rDNA technology, supplied as an injectable solution for subcutaneous or intravenous use, typically at a concentration of 100 U/mL. The prescription‑only medication belongs to the insulin class of antidiabetic agents and is indicated for type 1 or type 2 diabetes requiring insulin therapy in clinical practice.

Humulin S is used as short‑acting insulin to control blood glucose levels in patients with diabetes.

- Patients with type 1 diabetes mellitus who require a rapid‑acting insulin to replace endogenous secretion. - Adults or children with type 2 diabetes mellitus when diet, exercise, and oral agents do not achieve target glycaemia. - Temporary insulin coverage for peri‑operative periods, acute illness, or steroid‑induced hyperglycemia. - Supplemental insulin in continuous subcutaneous insulin infusion (CSII) pumps as the rapid‑acting component. - Adjustment of basal‑bolus insulin regimens to cover meals and correct post‑prandial spikes.

Adverse reactions to Humulin S are reported in clinical use; they range from mild, transient events to rare but serious conditions.

Common: - Hypoglycemia, presenting as dizziness, sweating, or confusion. - Injection‑site reactions such as pain, redness, or swelling. - Lipodystrophy or localized fat accumulation at the site. - Transient weight gain due to fluid retention.

Serious: - Severe hypoglycemia with loss of consciousness or seizures. - Anaphylactic reaction, including hives, airway swelling, or hypotension. - Edema or worsening heart failure in susceptible patients. - Hypokalemia resulting from rapid intracellular shift of potassium. - Insulin antibody formation interfering with glucose monitoring.

When prescribing Humulin S, clinicians should consider several safety considerations to minimize risk.

- Assess renal and hepatic function, as impairment may prolong insulin action. - Monitor blood glucose closely during initiation and dose adjustments to avoid hypoglycemia. - Use caution in patients with a history of severe allergic reactions to insulin or excipients. - Adjust doses in pregnant or lactating women only under medical supervision. - Educate patients on proper injection technique to prevent lipodystrophy and dosing errors. - Review concomitant medications that can potentiate hypoglycemia, such as sulfonylureas. - Consider cardiovascular status; edema may exacerbate heart failure.

Humulin S may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Concurrent use with other rapid‑acting insulins or high‑dose sulfonylureas, which can cause severe hypoglycemia. - Beta‑blockers in patients prone to hypoglycemia, as they may mask warning symptoms.

Use with caution: - Oral antihyperglycemics (e.g., metformin, DPP‑4 inhibitors) – dose adjustments may be needed. - Corticosteroids – may increase insulin requirements. - Diuretics, especially thiazides – can affect potassium balance and glucose levels. - MAO‑inhibitors – may potentiate insulin’s hypoglycemic effect.